01 / The problem
Clinical trials tell us whether a drug is safe, whether it works, and for whom. But each answer costs years, capital, and human risk—and most of that learning stays trapped inside one program.
02 / Tissue + AI
Gene circuits pioneered at MIT turn patient-derived stem cells into living, three-dimensional human tissue.
Each experiment trains a reusable Virtual Organ across donors, drugs, doses, schedules, and programs. The model predicts untested conditions and selects the next experiment.
03 / The team
Max RyeCEO & Cofounder
Repeat founder who has raised $40M+ and built biopharma teams and partnerships across the US and Asia.
LinkedIn ↗
Ron Weiss, PhDChief Scientist & Cofounder · MIT
MIT professor and synthetic-biology pioneer whose lab created Somerra's programmable-organoid methods.
LinkedIn ↗
Jenhan Tao, PhDHead of AI & Cofounder
As an early scientist at Generate:Biomedicines, he built and scaled ML systems for protein design, supporting programs advancing toward the clinic.
LinkedIn ↗04 / News & contact
Resilience 10 cohortOne sample. A living system that keeps learning.
